VICTORIA Proteomics identified 3 HFrEF subgroups with varying risk for CVD or HFH; externally validated; GDF-15 was key discriminator @justinezekowitz @AdriaanVoors @CindyWesterhout @lamcardio PalakShahMD @JavedButler1 @coconnormd @CVC_UAlberta @ISHVNews https://t.co/AxZLVhDsBn

Great start of day 2️⃣ of the #HFA clinical trials in #heartfailure course 🔥 taking a deep dive in statistics ➡️ ‘balance account of the totality of evidence’ 🔥 @WilfriedMullens challenging hospitalization endpoints in HF trial - paper accepted in @EJHFEiC

🫀Frailty matters in #HeartFailure care How do we move from trial evidence to tailored treatment decisions? Join the #HFAJournalClub 1 Oct 2025 | 18.00 - 19.00 CET 🎙️Host: Dr Floran Sahiti 🎙️Speakers: Prof #PardeepJhund, Prof @NicolasGirerd , Dr Massar Omar 🔗Register here ➡️

📢 Introducing JROADHF-NEXT database 🇯🇵 Nationwide, multicenter prospective registry for hospitalized HF 🔹 Enrollment: 2018–2021 🔹 4016 patients, 87 hospitals 🔹 Biobank: serum, plasma, and urine samples strored from ≈3000 pts 🔹 Avg age 73y, 61% male 🔹 2-yr follow-up: 88%

HOTLINES ESC 2025 Madrid HOT LINE 1 29 August from 11:00 to 12:00 Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study The DIGIT-HF trial will provide

Loved the commentary of Prof. #Lund about this proof of concept study on #GeranylGeranylAcetone (GGA) in #HFpEF. Although results were neutral, we absolutely need more of these trials! I’d love to see larger cohorts & deep HFpEF phenotyping. Kudos to Dr. #Voordes & colleagues!

In @ESCHeartFailure: Signs of congestion have varied prognostic value. 📌 Oedema & orthopnoea = strongest links to poor QoL 📌 Elevated JVP = key predictor of 60-day HF rehospitalization 📌 Lower QoL = higher rehospitalization risk 🔗  https://t.co/D6UHyNk30O @escardio

This study by Venema, Wykrzykowska et al showed that patients with aortic stenosis and features of HFpEF develop symptoms earlier and have a reduced symptomatic response, no significant decline in NT‐proBNP, and higher cardiovascular mortality after TAVI.

Clinical and #Proteomic Risk Profiles of New-Onset #HeartFailure in Men and Women From the UK Biobank HF ; 📌HF incidence: 3.6/1,000 men vs. 1.72/1,000 women (P<0.001). 📌Strongest risk factors: MI in men (HR: 2.61), #AFib in women (HR: 4.10). 📌#HTN & obesity contributed

📊Analysis of 1078 pts in #STRONG_HF: 📍Rapid #GDMT uptitration (~80% dose by day 90) is safe, feasible & ⬇️#HF readmissions/mortality in pts w/wo #AFib 📍#AFib shouldn’t be a barrier, all #HF pts deserve optimal care #GDMTworks 🔗 https://t.co/k0fUqthKWN #JACCHF #Epeeps

🌟 Abstract submissions are now OPEN for the next #HFA_ESC Congress #HeartFailure2025 ! Share your research or clinical case to gain global recognition, network with experts, and shape the future of heart failure care. 📅 Deadlines: Abstracts: 9 Jan Clinical Cases: 21 Jan

⏰ now is the time to submit your #science for #heartfailure2025 Grab your 💻 and a ☕️ and submit your #abstract before 📆 January 10th 🙋‍♀️ member of the #HFAYoung? Participate in the Young Investigator Award 🏆 and apply for a travel grant 🧳 ➡️ https://t.co/yonu8zWcOO

After a successful first #HFA journal club 📖 make sure you don’t miss our 2️⃣nd edition! #HFAYoung ❓Get to know more about the rapidly evolving treatment options for #HCM and discuss the ins and out of SEQOUIA-HCM 🫀 📆 October 23rd ⏰ 18:00 CEST Register now ⬇️

US trends in HF hospitalizations and HF-related mortality from 2010 to 2021 suggest that something has gone terribly wrong!

The #DECISION trial will evaluate the efficacy of the addition of #digoxin to current HF therapies in patients with #heartfailure #HFrEF #HFmrEF, check out the design paper of this RCT: doi:10.1002/ejhf.3428

#DECISION and #DIGIT_HF will inform on the relevance of digitalis glycosides in #HFrEF in patients on current #GDMT‼️ ➡️ #DIGIT_HF will report in 2025 See also our viewpoint article in #EHJ 2023 https://t.co/nzNZTd3nfD @DavidDuncker @SamiraSoltaniMD @rudolf_deboer

🔥#DECISION A new #RCT on #digoxin in #HF with #LVEF < 50% both sinus rhythm & #AF Will be the last trial on the topic? Maybe with a final answer 🍀 #HFUA @ESC_Journals @EJHFEiC @AmrAbdin10 @HanCardiomd @MicheleEmdin @gcfmd @JJheart_doc @ShelleyZieroth @KTamirisaMD

❓Weet u wat #hartfalen is? Lees meer hierover in het verhaal van Rianne: https://t.co/CrOLvwoymp en kom naar ons hartfalen symposium in het @umcg 🫀 📆 24 april ⏰ 13:00-17:00 📍 Fonteinpatio #UMCG

"Sex differences in anatomy, physiology, pharmacokinetics, pharma-codynamics and psychosocial factors might influence the response to pharmacological agents, device therapy and cardiac rehabilitation in patients with HF." https://t.co/PVgf9YAK8b

Well done Janice and Hallun! https://t.co/IitXkrxEAq